Site Editor

Soo Park, MD


AAD 2024: ‘Sustained’ Activity Reported With Sonidegib in Locally Advanced Basal Cell Carcinoma

By: Julia Fiederlein Cipriano, MS
Posted: Thursday, March 21, 2024

An analysis of the double-blind, multicenter phase II BOLT trial, which was presented as a poster during the 2024 American Academy of Dermatology Association (AAD) Annual Meeting (Poster 54233), showed robust and sustained durations of response for patients with locally advanced basal cell carcinoma who achieved a complete or partial response after treatment with 200 mg of sonidegib, according to Michael R. Migden, MD, of The University of Texas MD Anderson Cancer Center, Houston, and colleagues. This Hedgehog pathway inhibitor has been approved in the United States in the treatment of those who have this type of skin cancer and are not eligible for curative surgery or radiotherapy.  

A total of 66 patients were randomly assigned to receive the aforementioned dose of sonidegib. Tumors were evaluated via color photography and MRI per central review. The investigators classified a treatment response as a complete response, partial response, or stable disease.

In patients who achieved a complete response, the duration of response rates at 12, 18, 30, and 42 months were 74%, 67%, 27%, and 0% (not estimable) with MRI vs 89%, 53%, not estimable, and not estimable with photography, respectively. The rates were 58%, 39%, 16%, and not estimable with MRI vs 67%, 51%, 0% (not estimable), and 0% (not estimable) with photography, respectively, in those who achieved a partial response. Patients with stable disease demonstrated rates of 67%, 67%, 67%, and not estimable with MRI vs 29%, 24%, not estimable, and not estimable with photography, respectively.

Disclosure: For full disclosures of the study authors, visit

By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.